India Pharma Outlook Team | Friday, 03 October 2025
Parexel, one of the largest and most successful global clinical research organizations (CRO), has entered into a partnership deal with Weave Bio, a trailblazer in AI-native regulatory automation management systems, to simplify regulatory filing procedures and shorten the time to market of new treatments.
Within the same partnership, Parexel will be the CRO design partner and adopt its broad knowledge in clinical, non-clinical, clinical pharmacology, and chemistry, manufacturing, and controls (CMC) to improve the Weave AI platform and product pipeline. Parexel will also be exclusive as the only CRO to use Weave solutions post new product launches.
“This partnership represents a significant advancement in Parexel’s vision to leverage AI to speed clinical research processes, enhance first-time quality and accelerate the delivery of life-changing therapies to patients,” said Paul Bridges, President, Consulting, Parexel.
Also Read: Oral GLP-1 Drugs: Expanding Patient Access in Obesity and Diabetes Care
Parexel is already applying Weave flagship AutoIND tool to Investigational New Drug (IND) applications, where it completed the applications 50 percent ahead of schedule compared to standard schedules. These efficiency advantages allow high-quality INDs to be prepared at ground-breaking rate to assist sponsors to commence new clinical trials faster.
Lindsay Mateo, Chief Commercial Officer, Weave, noted, “AI tools are only as strong as the people behind them. Human experts provide the context that guides our platform and help translate its findings into action. Through this partnership, Weave will tap into Parexel’s deep regulatory expertise to refine and expand our solutions across the drug development industry.”
RAPS Convergence, October 7-9, will feature Parexel and Weave demonstrating their collaboration and thought leadership discussions of AI-infused regulatory processes.
